World-renowned astronaut Koichi Wakata to speak at Florida Poly commencement
"It is a true honor to join the 2026 graduates of Florida Polytechnic University as they embark on their own journey as a new generation of explorers," said Dr.
Upon retiring from the Japan Aerospace Exploration Agency (JAXA) in 2024, Wakata's accomplishments included five space missions, more than any other Japanese astronaut. During his time on the ISS, Wakata completed two spacewalks for a total of 14 hours and two minutes and operated four of the station's robotic systems.
Florida Poly leaders said his remarkable career reflects the ambition and pursuit of excellence celebrated at commencement for the state's only university exclusively dedicated to STEM education.
"
As Astronaut and CTO of Axiom Space, Wakata currently leads the expansion of its business strategies in the
Wakata said he hopes to share insights from his career in engineering and exploration to encourage graduates to reach beyond boundaries in their quest for knowledge and discovery.
"Throughout my career I've learned boundaries are often starting points for discovery," Wakata said. "When faced with challenges or uncertainty, I've learned that leading with curiosity and discipline builds a strong foundation for a life of exploration and deep fulfillment."
Wakata earned a Ph.D. in aerospace engineering, master's degree in applied mechanics, and bachelor's degree in aeronautical engineering from Kyushu University in
Florida Poly's 2026 commencement will take place at
View original content to download multimedia:https://www.prnewswire.com/news-releases/world-renowned-astronaut-koichi-wakata-to-speak-at-florida-poly-commencement-302745105.html
SOURCE Florida Polytechnic University
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hard Rock Hotel Malta Celebrates Star-Studded Grand Opening in St. George's Bay
- Virtus Convertible & Income Fund II Announces Quarterly Distribution: 5.500% Series A Cumulative Preferred Shares
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share